Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A First-in-human (FIH) Clinical Trial to Investigate the Human Monoclonal Antibody NG004, Administrated Intrathecally in Acute Spinal Cord Injury (SCI) Patients

NCT06817577 is registered in ClinicalTrials.gov with NovaGo Therapeutics AG as lead sponsor.

NCT NCT06817577
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06817577 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A First-in-human (FIH) Clinical Trial to Investigate the Human Monoclonal Antibody NG004, Administrated Intrathecally in Acute Spinal Cord Injury (SCI) Patients
Lead sponsor
NovaGo Therapeutics AG
Phase
Phase 1
Overall status
Active, not recruiting
Start date
December 18, 2024
Completion date
March 31, 2027
Enrollment
20 (estimated)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

acute spinal cord injury (sci), central nervous system diseases, nervous system diseases, spinal cord diseases, spinal cord injuries (sci), trauma, nervous system, wounds and injuries